Education
About Us
Working with TipRanks
Follow Us
Alaunos Therapeutics (TCRT)
NASDAQ:TCRT
TCRT Stock Chart & Stats
$3.54
-$0.04(-2.13%)
At close: 4:00 PM EST
$3.54
-$0.04(-2.13%)
Day’s Range― - ―
52-Week Range$1.31 - $6.20
Previous CloseN/A
Volume6.23K
Average Volume (3M)860.99K
Market Cap
$7.90M
Enterprise Value$3.47M
Total Cash (Recent Filing)$1.94M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-1.28
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,231,829
10 Day Avg. Volume2,529,145
30 Day Avg. Volume860,987
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.48
Price to Sales (P/S)305.84
P/FCF Ratio-0.62
Enterprise Value/Market Cap0.44
Enterprise Value/Revenue578.84
Enterprise Value/Gross Profit-19.40
Enterprise Value/Ebitda-0.87
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Alaunos Therapeutics News
TCRT FAQ
What was Alaunos Therapeutics’s price range in the past 12 months?
Alaunos Therapeutics lowest stock price was $1.31 and its highest was $6.20 in the past 12 months.
What is Alaunos Therapeutics’s market cap?
Alaunos Therapeutics’s market cap is $7.90M.
When is Alaunos Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Alaunos Therapeutics’s earnings last quarter?
Currently, no data Available
Is Alaunos Therapeutics overvalued?
According to Wall Street analysts Alaunos Therapeutics’s price is currently Overvalued.
Does Alaunos Therapeutics pay dividends?
Alaunos Therapeutics does not currently pay dividends.
What is Alaunos Therapeutics’s EPS estimate?
Alaunos Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alaunos Therapeutics have?
Alaunos Therapeutics has 2,231,829 shares outstanding.
What happened to Alaunos Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Alaunos Therapeutics?
Currently, no hedge funds are holding shares in TCRT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alaunos Therapeutics
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
Technical Analysis
Ownership Overview
13.90% Insiders
2.39% Mutual Funds
<0.01% Other Institutional Investors
83.08% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---